Imagion Biosystems Ltd. · ASX:IBX

Imagion Biosystems — Emerging Growth Conference (October 2025)

18 slides from Imagion Biosystems's conference presentation, October 2025

  1. Slide 1: IBX Investor Deck – Emerging Growth Conference

    IBX Investor Deck – Emerging Growth Conference Copyright Oct 2025

  2. Slide 2: IBX Investor Deck - Emerging Growth Conference Copyright Oct 2025

    IBX Investor Deck - Emerging Growth Conference Copyright Oct 2025

  3. Slide 3: IBX Investor Deck - Emerging Growth Conference Copyright Oct 2025

    • • ¾ ¾ ¾ IBX Investor Deck - Emerging Growth Conference Copyright Oct 2025

  4. Slide 4: Cancer Diagnostics - $100B Market

    CANCER DIAGNOSTICS - $100B MARKET 7% CAGR $30,000 28% 27% $26,044 $25,000 100% 92% $20,136 Millions $20,000 $15,541 $15,000 $7,246 $9,632 $10,000 $8,850 $5,908 $3,055 $4,583 $5,000 4% 24% $- Blood Pancreatic Kidney Ovarian Liver Prostate Colorectal Breast Lung 54% 99% * Source: Transparency Market R

  5. Slide 5: IBX Investor Deck - Emerging Growth Conference Copyright Oct 2025

    IBX Investor Deck - Emerging Growth Conference Copyright Oct 2025

  6. Slide 6: IBX Investor Deck - Emerging Growth Conference Copyright Oct 2025

    IBX Investor Deck - Emerging Growth Conference Copyright Oct 2025

  7. Slide 7: IBX Investor Deck - Emerging Growth Conference Copyright Oct 2025

    IBX Investor Deck - Emerging Growth Conference Copyright Oct 2025

  8. Slide 8: IBX Investor Deck - Emerging Growth Conference Copyright Oct 2025

    IBX Investor Deck - Emerging Growth Conference Copyright Oct 2025

  9. Slide 9: IBX Investor Deck - Emerging Growth Conference Copyright Oct 2025

    • • IBX Investor Deck - Emerging Growth Conference Copyright Oct 2025

  10. Slide 10: IBX Investor Deck – Emerging Growth Conference Copyright Oct 2025

    • • • • • • • • • • • IBX Investor Deck – Emerging Growth Conference Copyright Oct 2025

  11. Slide 11: Copyright Oct Copyright 2025 Oct 2025

    • • 9 • 9 ❌ ❌ 9 ❌ 9 ❌ IBX Investor Deck – Emerging Growth Conference Copyright Oct Copyright 2025 Oct 2025

  12. Slide 12: Clinical Development Plan and Key Milestones

    Clinical Development Plan and Key Milestones Key Next Steps IND HER2+ File IND and initiate Breast Phase 1 Pre-IND Phase 2 Phase 3 Phase 2 study for HER2 Cancer Dose and Image Protocol Optimization imaging agent IND Ovarian Cancer Pre-Clinical IND-enabling Phase 1 Phase 2 Complete IND Human Safety e

  13. Slide 13: Costs by Category: SOC versus MagSense

    Costs by Category Associated with SOC versus MagSense per 1,000 patients $5.0 Complications $4.5 $0.3 $0.2 SLNB Costs in Millions (USD) $4.0 $1.0 $3.5 ALND $3.0 $2.5 $0.5 $2.5 MRI $0.5 $0.0 $2.0 Ultrasound Guided FNA $1.5 $0.6 Biopsy $1.0 $2.1 $0.5 Clincal $0.5 Assessment/MagSense $0.3 $0.3 $0.0 SOC

  14. Slide 14: Acquirer Target Value AUD

    Acquirer Target Value AUD Year Notes $18M 2024 $310M 2024 $1.6B 2018 $328M Est. 2019 $3.9B 2018 IBX Investor Deck - Emerging Growth Conference Copyright Oct 2025

  15. Slide 15: IBX Investor Deck – Emerging Growth Conference Copyright Oct 2025

    • • • • • • • IBX Investor Deck – Emerging Growth Conference Copyright Oct 2025

  16. Slide 16: IBX Investor Deck - Emerging Growth Conference Copyright Oct 2025

    • • • • • • IBX Investor Deck - Emerging Growth Conference Copyright Oct 2025

  17. Slide 17: IBX Investor Deck - Emerging Growth Conference Copyright Oct 2025

    • • • • • • • IBX Investor Deck - Emerging Growth Conference Copyright Oct 2025

  18. Slide 18: IBX Investor Deck – Emerging Growth Conference Copyright Oct 2025

    IBX Investor Deck – Emerging Growth Conference Copyright Oct 2025

Imagion Biosystems — Emerging Growth Conference (October 2025) on 6ix